Effect of Adenylyl Cyclase Type 6 on Localized Production of cAMP by Beta-2 Adrenoceptors in Human Airway Smooth Muscle Cells

1Shailesh R. Agarwal, 1Chase Fiore, 1Kathryn Miyashiro,
2Rennolds S. Ostrom, and 1Robert D. Harvey

1Department of Pharmacology,
University of Nevada, Reno School of Medicine, Reno NV 89557
and
2Department of Biomedical and Pharmaceutical Sciences,
Chapman University School of Pharmacy, Irvine, CA 92618
Running Title: cAMP Compartmentation in Airway Smooth Muscle

Address for Correspondence: Robert D. Harvey

Department of Pharmacology
University of Nevada, Reno
1664 N. Virginia Street, MS 573
Reno, NV 89557
Tel 775-784-4119
Fax 775-784-1620
Email: rdharvey@med.unr.edu

Text pages: 31
Tables: 0
Figures: 6
References: 31
Abstract words: 249
Introduction words: 748
Discussion words: 868
Abbreviations:

AC6, adenylyl cyclase type 6; AKAP, A kinase-anchoring protein; ASM, airway smooth muscle; β2AR, β2-adrenoceptor; ECFP, enhanced cyan fluorescent protein; EP2R, EP2 prostaglandin receptor; Epac2-camps, exchange protein activated by cAMP type 2-based cAMP biosensor; Epac2-CAAX, Epac2-camps biosensor with a prenylation targeting sequence; Epac2-MyrPalm, Epac2-camps biosensor with an acylation targeting sequence; EYFP, enhanced yellow fluorescent protein; FRET, fluorescence resonance energy transfer; Fsk, forskolin; IBMX, 3-isobutyl-1-methylxanthine; Iso, isoproterenol; PDE4, phosphodiesterase type 4; PKA, protein kinase A

Recommended Section Assignment: Cellular and Molecular
Abstract

β2-Adrenoceptors (β2ARs) are concentrated in caveolar lipid raft domains of the plasma membrane in airway smooth muscle (ASM) cells, along with adenylyl cyclase type 6 (AC6). This is believed to contribute to how these receptors can selectively regulate certain types of cAMP-dependent responses in these cells. The goal of the present study was to test the hypothesis that β2AR production of cAMP is localized to specific subcellular compartments using fluorescence resonance energy transfer (FRET)-based cAMP biosensors targeted to different microdomains in human ASM cells. Epac2-MyrPalm and Epac2-CAAX biosensors were used to measure responses associated with lipid raft and non-raft regions of the plasma membrane, respectively. Activation of β2ARs with isoproterenol produced cAMP responses most readily detected in lipid raft domains. Furthermore, overexpression of AC6 somewhat paradoxically inhibited β2AR production of cAMP in lipid raft domains, without affecting β2AR responses detected in other subcellular locations or cAMP responses to EP2 prostaglandin receptor activation, which were confined primarily to non-raft domains of the plasma membrane. The inhibitory effect of overexpressing AC6 was blocked by inhibition of phosphodiesterase type 4 (PDE4) activity with rolipram, inhibition of protein kinase A (PKA) activity with H89, and inhibition of A kinase anchoring protein (AKAP) interactions with the peptide inhibitor Ht31. These results support the idea that overexpression of AC6 leads to enhanced feedback activation of PDE4 via phosphorylation by PKA that is part of an AKAP-dependent signaling complex. This provides insight into the molecular basis for localized regulation of cAMP signaling in human ASM cells.
Introduction

β2-adrenoceptor (β2AR) agonists are a mainstay of therapy for asthma, chronic obstructive pulmonary disease and other respiratory disorders. β2AR activation induces airway smooth muscle (ASM) relaxation and bronchodilation by stimulating adenylyl cyclase (AC) activity and the production of cAMP. While cAMP plays a central role in regulating the contractile state of ASM (Pelaia et al., 2008; Noble et al., 2014), this ubiquitous signaling molecule is also involved in eliciting a number of other responses in the muscle cells that make up this tissue (Billington et al., 2013). The specific effect mediated by cAMP often depends on the signaling pathway responsible for its production. In ASM cells, cAMP production is regulated by both β2ARs and EP2 prostaglandin receptors (EP2Rs) (Bogard et al., 2011). Production of cAMP by either type of receptor is capable of causing human ASM relaxation. However, only cAMP produced by β2ARs stimulates cytoskeletal reorganization and cell shape changes associated with arborization and only cAMP produced by EP2Rs increases the expression of the cytokine IL-6 (Bogard et al., 2012; Bogard et al., 2014).

Understanding how cells compartmentalize cAMP and generate unique responses upon activation of a given receptor is important, because it may help explain why β2AR agonists, which are widely used as bronchodilators, suffer from issues with tachyphylaxis due to receptor desensitization (Penn et al., 1998) and increased adverse effects (Taylor, 2009).

The simplest way to explain the ability of different receptors to illicit unique functional responses is if each receptor stimulates cAMP production that is confined to distinct
subcellular locations. However, for this to be true, these receptors must then be
distributed in distinctly different physical locations. Consistent with this hypothesis,
\( \beta_2 \text{ARs} \) and \( \text{EP}_2 \text{Rs} \) have been found to reside in different fractions of the plasma
membrane (Ostrom et al., 2001; Bogard et al., 2011; Bogard et al., 2012). Most cell
membranes contain cholesterol- and sphingomyelin-rich domains referred to as lipid
rafts, which form buoyant membrane fractions on a sucrose density gradient (Insel et
al., 2005; Ostrom and Insel, 2006). Caveolae are represented by a subset of the
buoyant fractions associated specifically with caveolins, which are scaffolding proteins
involved in forming signaling complexes. In human ASM cells, \( \beta_2 \text{ARs} \) are found
specifically in caveolar, lipid raft fractions of the plasma membrane, while \( \text{EP}_2 \text{Rs} \) are
found in the non-raft membrane fractions (Bogard et al., 2011).

ASM responses to \( \beta_2 \text{AR} \) and \( \text{EP}_2 \text{R} \) stimulation have also been attributed to activation of
different isoforms of adenylyl cyclase (AC), the enzyme responsible for cAMP
production. AC type 6 (AC6) is found specifically in caveolar membrane fractions of
ASM cells, and its overexpression selectively enhances \( \beta_2 \text{AR} \) production of cAMP and
cAMP-dependent arborization. AC type 2 (AC2) is found exclusively in non-raft fractions
of the plasma membrane, and its overexpression selectively enhances \( \text{EP}_2 \text{R} \) stimulation
of cAMP and cAMP-dependent production of IL-6 (Bogard et al., 2011; Bogard et al.,
2012; Bogard et al., 2014).

The purpose of the present study was to test the hypothesis that in primary human ASM
cells \( \beta_2 \text{AR} \) stimulation preferentially enhances cAMP production in subcellular locations
associated with lipid raft domains of the plasma membrane by a mechanism involving activation of AC6. This was done by comparing cAMP responses detected by Epac2-camps, a FRET-based biosensor, expressed in different subcellular locations (Nikolaev et al., 2004). Epac2-camps itself has no targeting sequences and is expressed throughout the cytoplasmic domain. Epac2-MyrPalm is a version of the probe that contains an acylation sequence targeting it to lipid raft domains of the plasma membrane, and Epac2-CAAX contains a prenylation sequence that targets the probe to non-raft domains of the plasma membrane. These sequences have been previously shown to target proteins to lipid raft and non-raft fractions of the plasma membrane of various cell types (Melkonian et al., 1999; Zacharias et al., 2002; Depry et al., 2011). Furthermore, our previous work has also demonstrated that probes targeted using these sequences are capable of detecting differences in responses produced by receptors located in lipid raft and non-raft membrane domains of various cell types (Agarwal et al., 2014; Agarwal et al., 2017; Agarwal et al., 2018). In human ASM cells, we demonstrated the EP2Rs preferentially couple to AC2 to produce changes in cAMP that are confined primarily to non-raft domains of the plasma membrane (Agarwal et al., 2017). In the present study, we demonstrate that β2ARs produce responses that are primarily associated with lipid raft domains. Furthermore, AC6 regulates this response through a mechanism that involves direct interaction with protein kinase A (PKA) and positive feedback activation of PDE4.
**Materials and Methods**

**Cell Culture.** Human ASM cells were derived from tracheae and primary bronchi from non-asthmatic human donors by Dr. Raymond Penn (Thomas Jefferson University) and Dr. Reynold Panettieri (Rutgers University), as described previously (Yan et al., 2011). These cells come from de-identified biological samples that are considered exempt by the University of Nevada, Reno and Chapman University Institutional Review Boards. Experiments were conducted using multiple samples of primary cells derived from six different patients representing both sexes. All cells used were between passage 6 and 9. Cells were maintained in Ham’s F12 nutrient mixture supplemented with 10% fetal bovine serum, 100 units/ml penicillin, 100 µg/ml streptomycin. Cells were transduced with adenovirus constructs containing Epac2-based cAMP biosensors for 48-72 hours. For overexpression experiments, adenoviral constructs expressing AC6 and/or Ht31 were used at titers previously shown to produce >90% transduction efficiency (Bogard et al., 2011). All experiments were conducted at room temperature.

**FRET Microscopy.** The Epac2-camps, Epac2-MyrPalm, and Epac2-CAAX biosensors used in the present study have been previously characterized (Nikolaev et al., 2004; Agarwal et al., 2014; Agarwal et al., 2017; Agarwal et al., 2018). All three probes have a similar affinity for activation by cAMP (Agarwal et al., 2014). Live cell imaging experiments were conducted as described previously (Warrier et al., 2005; Warrier et al., 2007; Iancu et al., 2008; Agarwal et al., 2017). Briefly, cells were bathed in the following solution (in mM): NaCl 137, KCl 5.4, MgCl2 0.5, CaCl2 1.0, NaH2PO4 0.33, glucose 5.5, and HEPES 5 (pH 7.4). FRET imaging was conducted using an Olympus IX71 inverted microscope (Olympus America, Center Valley, PA, USA).
equipped with a Hamamatsu OrcaD2 dual chip CCD camera and HCImage data acquisition and analysis software (Hamamatsu Corporation, Bridgewater, NJ, USA). Images were obtained with a 40x water-immersion objective (1.3 numerical aperture). ECFP excitation was achieved by using a 300-W xenon arc lamp with a D436/20 band-pass filter and a 455DCLP dichroic mirror. ECFP and EYFP (FRET) emissions were measured simultaneously using a 505DCXR dichroic mirror with D480/30 and D535/30 band-pass filters. Changes in cAMP activity were defined as the change in background and bleed-through corrected ECFP/EYFP fluorescence intensity ratio (ΔR) relative to the baseline ratio (R₀) measured in a region of interest. As long as the nucleus was avoided, moving the ROI did not significantly affect the results. Ratiometric measurements also ensured that the responses measured were independent of the level of expression of the probes. FRET ratios were measured once every 10 seconds. A baseline of at least 5 min was established prior to the application of any drug. Because the response to low concentrations of agonists were relatively slow to develop, all drugs were applied for at least 10 min before measuring their effects. Responses were calculated relative to the average ratio measured over the 30 s period immediately preceding application of any drug. To control for any differences in the dynamic range of the FRET responses produced by the different probes, all results were normalized to the magnitude of the maximal probe response observed in the same cell following exposure to maximally stimulating concentrations 3-isobutyl-1-methylxanthine (IBMX), a non-specific PDE inhibitor, plus forskolin, a direct activator of AC activity.

Materials. Ham’s F12 medium, penicillin, streptomycin, and fetal bovine serum were purchased from Life Technologies (Carlsbad, CA, USA). Rolipram and forskolin
were obtained from Tocris Bioscience (Bristol, UK). All other reagents were purchased from Sigma-Aldrich (St. Louis, MO, USA).

Statistics. All data are expressed as the mean ± SEM of the indicated number of experiments conducted using different cells ($n$) obtained from different preparations ($N$). Statistical significance ($P < 0.05$) was determined by Student's t-test with Holm-Sidak correction, where appropriate, using SigmaPlot (Systat Software, San Jose, CA, USA).
Results

Responses to β2AR stimulation were measured using submaximally stimulating concentrations of the agonist isoproterenol (Iso). In control cells, exposure to 1 nM Iso elicited responses that were detected by the cytosolic (Epac2-camps) and lipid raft (Epac2-MyrPalm) targeted probes, but not by the non-raft targeted (Epac2-CAAX) probe (figure 1A). Exposure to 3 nM Iso elicited responses detected by all three probes, although the response detected by Epac2-CAAX was significantly smaller (figure 1C). These results are consistent with the idea that β2ARs are primarily concentrated in lipid raft domains of the plasma membrane of human ASM cells.

We then examined the effect of overexpressing adenylyl cyclase type 6 (AC6). This did not affect the responses to maximally stimulating concentrations of forskolin plus IBMX (see supplement figure 1). However, it did significantly reduce the relative magnitude of the response to β2AR stimulation detected by Epac2-MyrPalm (P < 0.05), without altering the responses detected by Epac2-camps or Epac2-CAAX (P > 0.05) (figure 1B, C). This supports the idea that AC6 is targeted primarily to lipid raft domains of the plasma membrane, where it affects β2AR-mediated production of cAMP. Despite the fact that AC6 overexpression selectively altered β2AR responses associated with lipid raft domains, our original hypothesis was that it would enhance the production of cAMP. Contrary to this prediction, AC6 overexpression actually inhibited the β2AR response detected by Epac2-MyrPalm.
To determine if the effect of overexpressing AC6 is specific to β2ARs, we also looked at the effect it had on responses to EP2 prostaglandin receptor (EP2R) activation using the agonist butaprost. As reported previously, in control cells, butaprost elicited cAMP responses that were most readily detected by the Epac2-CAAX probe in non-raft domains of the plasma membrane (figure 2A) (Agarwal et al., 2017). Furthermore, overexpressing AC6 neither enhanced nor inhibited cAMP responses to butaprost (P > 0.05) (figure 2B, C) detected by any of the probes. This further supports the idea that AC6 is selectively associated with regulating β2AR responses in lipid raft domains of the plasma membrane.

We hypothesized that AC6 overexpression causes a localized decrease in cAMP produced by β2ARs in lipid raft domains as a result of an increase in phosphodiesterase (PDE) activity through a positive feedback mechanism involving protein kinase A (PKA) (Conti and Beavo, 2007). The activity of PDE4, which is prominent in airway smooth muscle cells (Méhats et al., 2003; Bogard et al., 2012), has been shown to be upregulated by PKA-dependent phosphorylation. To examine this possibility, we looked at the effect of rolipram (10 µM), a selective PDE4 inhibitor, on β2AR responses in control cells as well as cells overexpressing AC6 (figure 3). Rolipram by itself had no effect on cAMP activity detected by the Epac2-MyrPalm probe in either control or AC6 overexpressing cells (P > 0.05). Furthermore, rolipram did not appear to alter the magnitude of the response to Iso in control cells (figure 3A). However, it did significantly alter the response to Iso in AC6 overexpressing cells (figure 3B, C). In the presence of rolipram, the response to Iso was not significantly different from control cells (P > 0.05).
This is in contrast to the significant decrease in magnitude of the β₂AR response associated with AC6 overexpression in the absence of PDE4 inhibition (see figure 1). Furthermore, this effect appeared to be specific for responses associated with lipid raft domains, as rolipram did not enhance the response to Iso detected by Epac2-CAAX in non-raft domains of AC6 overexpressing cells (figure 3B, C), it was the same size as the response to Iso in control cells in the absence of rolipram (see figure 1A, C). This supports the idea that AC6 overexpression leads to a localized decrease in cAMP produced by β₂ARs associated specifically with lipid raft domains that is mediated by PDE4.

The above results are consistent with the hypothesis that overexpressing AC6 leads to an increase in cAMP production, which in turn acts in a positive feedback manner to enhance PDE4 activity, presumably through a mechanism involving PKA-dependent phosphorylation (Conti and Beavo, 2007). To examine this possibility, we compared the response to Iso in cells first exposed to the PKA inhibitor H89 (1 µM), to prevent the feedback activation of PDE4. The PKA inhibitor itself did not produce a change in basal cAMP activity (figure 4). However, H89 did appear to alter the Iso-stimulated cAMP response detected by Epac2-MyrPalm in AC6 overexpressing cells (figure 4B). In the presence of H89, the response to 3 nM Iso was not significantly different from control cells (P > 0.05) (figure 4C). Again, this is contrast to the significant decrease in magnitude of the β₂AR response associated with AC6 overexpression in the absence of H89 (see figure 1B, C). This effect appeared to be specific for responses associated
with lipid raft domains, as H89 did not enhance the β2AR responses detected in non-raft domains of AC6 overexpressing cells (figure 4C).

The above results support the idea that positive feedback activation of PDE4 contributes to the decrease in cAMP produced in response to β2AR stimulation in lipid raft domains of the plasma membrane, but only in AC6 overexpressing cells. This could be explained if overexpression of AC6 leads to recruitment of excess PKA activity. Adenylyl cyclases have been shown to be integral components of signaling complexes associated with type II PKA through interactions with A kinase anchoring proteins (AKAPs) (Dessauer, 2009). To determine if this type of interaction contributes to the effect of AC6 overexpression, we compared responses to Iso in cells overexpressing the Ht31 peptide, which disrupts PKA anchoring to AKAPs (Carr et al., 1992). We found that in the presence of the Ht31 peptide, the response to 3 nM Iso detected by Epac2-MyrPalm in cells overexpressing AC6 was no different in magnitude than the response observed in control cells (P > 0.05) (figure 5A, B). This suggests that the decrease in magnitude of the Iso response detected by Epac2-MyrPalm in AC6 overexpressing cells in the absence of Ht31 (see figure 1B, C) involves the recruitment of PKA activity to lipid raft domains where β2AR signaling occurs. Again, this effect appears to be specific for responses associated with lipid raft domains, as Ht31 did not alter the Iso response detected by Epac2-CAAX (P > 0.05) (figure 5A, B).
Discussion

In the present study, we found that activation of β2ARs with Iso caused an increase in cAMP activity that could be detected throughout the cytoplasmic domain of human ASM cells, as well subcellular locations associated with lipid raft and non-raft domains of the plasma membrane. However, changes associated with lipid raft domains were more sensitive to β2AR stimulation and larger than those associated with non-raft domains. Furthermore, overexpression of AC6 selectively altered β2AR production of cAMP in lipid raft domains, without affecting cAMP responses occurring in other locations or cAMP responses mediated by other receptors. In addition, the effect that AC6 overexpression had on β2AR responses in lipid raft domains was inhibitory, and this inhibitory effect could be blocked by inhibition of PDE4 activity, PKA kinase activity, as well as AKAP interactions with PKA.

The ability of AC6 overexpression to selectively alter β2AR responses associated with lipid raft domains is consistent with previous findings demonstrating that both signaling proteins are concentrated in caveolar fractions of the plasma membrane in ASMs (Bogard et al., 2011; Bogard et al., 2012). However, the fact that the AC6 overexpression produced an inhibitory effect in the present study was somewhat surprising. It was previously reported that overexpression of AC6 enhances cAMP production in response to direct activation of AC activity with forskolin or β2ARs with Iso. This apparent contradiction is most likely explained by the fact that the earlier studies measured cAMP activity in cell lysates using traditional immunoassay techniques that required the use of maximally stimulating concentrations of the non-specific PDE
inhibitor IBMX. The results of the present study suggest that the effects of AC6 overexpression are more subtle, in that they only appear to occur in specific subcellular locations and they can be blocked by selective inhibition of PDE4 activity. Therefore, the use of whole cell lysates and IBMX would have obscured the ability to detect the kind of response found presently, using targeted biosensors in intact cells.

The ability to block the effect of AC6 overexpression on β2AR responses with rolipram as well as the PKA kinase inhibitor H89 supports the idea that the inhibitory effect was due to an increase in PDE4 activity. It is well documented that PDE4 activity can be stimulated following phosphorylation by PKA (Conti and Beavo, 2007). It is conceivable that the increased expression of AC activity contributed to an initial increase in cAMP production upon β2AR stimulation that resulted in a rapid activation of PKA and subsequent phosphorylation of PDE4. If this was the case, one might have expected to see a rapid increase followed by a decrease in cAMP following exposure to Iso. One possibility is that it occurred too rapidly for us to detect, especially since we were only able to measure FRET responses once every 10 seconds. It could also be that the increase in cAMP needed to activate PKA occurred locally, within a signaling complex that may not have been accessible to the Epac2-MyrPalm biosensor, even though they are all associated with the same membrane domain.

Consistent with the idea that the β2AR and AC6 are part of a signaling complex that includes PKA is the fact that the inhibitory effect of AC6 overexpression was also blocked by the AKAP inhibitory peptide Ht31. This peptide mimics the AKAP anchoring
sequence that binds to the regulatory subunit of type II PKA. Preventing the anchoring of PKA would have limited the ability of local activation of PKA to phosphorylate PDE4. The implication is the PDE4 is also part of this signaling complex. Although we do not know which specific AKAP is involved, several different isoforms have been found to interact with certain AC subtypes and can regulate compartmentalized cAMP signaling (Horvat et al., 2012). For example, AKAP79/AKAP150/AKAP5 is able to interact with AC2, 3, 5, 6, 8, and 9 (Efendiev et al., 2010); yotiao/AKAP9 has been shown to interact with AC1, 2, 3, and 9 (Piggott et al., 2008); and mAKAPβ/AKAP6 is able to interact with AC2 and 5 (Kapiloff et al., 2009). Although the evidence presented in the current study supports the idea that AKAP anchoring of PKA is necessary to see the effect of AC6 overexpression, it is possible that the signaling complex, which appears to include β2ARs, AC6, PDE4, and PKA (figure 6), may involve other scaffolding proteins such as caveolins (Ostrom et al., 2012). In either case, inhibition of PDE4 activity might have been expected to affect β2AR responses detected by Epac2-MyrPalm in non-AC6 overexpressing cells (see figure 3A). One possible reason it did not is that other PDE isoforms are present that can compensate for the loss of PDE4 activity. Only when overexpression of AC6 recruits excess PDE4 activity to that microdomain is an effect apparent.

In conclusion, using targeted FRET-based biosensors, we were able to demonstrate that β2AR stimulation produces a compartmentalized cAMP response associated with lipid raft domains of the plasma membrane in human ASM cells. Furthermore, overexpression of AC6 activity revealed functional evidence that the β2AR is associated
with a signaling complex that includes AC6, PKA, and PDE4. These findings imply that therapeutic strategies involving combined β2AR activation and PDE4 inhibition might be particularly effective at increasing cAMP levels and bronchodilation in human ASM.
Acknowledgements

The authors thank Dr. Raymond Penn and Dr. Tonio Pera, Thomas Jefferson University, for supplying the human ASM cells.
Authorship Contributions

Participated in research design: Ostrom and Harvey

Conducted experiments: Agarwal, Fiore, and Miyashiro

Contributed new reagents or analytic tools: Harvey and Agarwal

Performed analysis: Agarwal, Fiore, and Miyashiro

Wrote or contributed to the writing of the manuscript: Agarwal, Ostrom, and Harvey
References

Compartmentalized cAMP Signaling Associated With Lipid Raft and Non-raft Membrane

Agarwal SR, Miyashiro K, Latt H, Ostrom RS and Harvey RD (2017)
Compartmentalized cAMP responses to prostaglandin EP2 receptor activation in human

Agarwal SR, Yang PC, Rice M, Singer CA, Nikolaev VO, Lohse MJ, Clancy CE and
Harvey RD (2014) Role of membrane microdomains in compartmentation of cAMP

Billington CK, Ojo OO, Penn RB and Ito S (2013) cAMP regulation of airway smooth

Bogard AS, Adris P and Ostrom RS (2012) Adenylyl cyclase 2 selectively couples to E
prostanoid type 2 receptors, whereas adenylyl cyclase 3 is not receptor-regulated in

Bogard AS, Birg AV and Ostrom RS (2014) Non-raft adenylyl cyclase 2 defines a cAMP
signaling compartment that selectively regulates IL-6 expression in airway smooth
muscle cells: differential regulation of gene expression by AC isoforms. *Naunyn
Schmiedebergs Arch Pharmacol* **387**:329-339.


Melkonian KA, Ostermeyer AG, Chen JZ, Roth MG and Brown DA (1999) Role of lipid modifications in targeting proteins to detergent-resistant membrane rafts. Many raft proteins are acylated, while few are prenylated. *J Biol Chem* **274**:3910-3917.


Footnotes

This work was supported by the National Institutes of Health [Grants R01 GM107094, R01 GM101928, and R01 HL145778]. SRA was supported by a National Institute of General Medical Sciences Center of Biological Research Excellence [P20 GM130459].
Figure Legends

**Figure 1** Changes in cAMP activity in different subcellular domains following β2AR stimulation. Representative time-course of changes in magnitude of FRET-response (ΔR/R₀) detected by Epac2-MyrPalm, Epac2-CAAX, and Epac2-camps biosensors following activation of β2ARs with 1 nM and 3 nM isoproterenol (Iso) in (A) untreated human airway smooth muscle (ASM) cells (control) and (B) human ASM cells overexpressing adenylyl cyclase type 6 (AC6 OE). Results are normalized to the magnitude of the maximal response produced by forskolin (FSK, 10 µM) and IBMX (100 µM) in the same cell. (C) Size of average FRET responses in control cells (black bars) and AC6 OE cells (red bars). AC6 OE caused a significant (P < 0.05, student’s t-test) decrease in the magnitude of the responses detected by Epac2-MyrPalm (control, n/N = 6/6; AC6 OE, n/N = 9/4), but not those detected by Epac2-CAAX (control, n/N = 7/6; AC6 OE, n/N = 6/6), or Epac2-camps (control, n/N = 6/3; AC6 OE, n/N = 5/3).

**Figure 2** Changes in cAMP activity in different subcellular domains following EP2R stimulation. Representative time-course of changes in magnitude of FRET-response (ΔR/R₀) detected by Epac2-MyrPalm, Epac2-CAAX, and Epac2-camps biosensors following activation of EP2Rs with 0.3 µM and 1 µM butaprost in (A) untreated human airway smooth muscle (ASM) cells (control) and (B) human ASM cells overexpressing adenylyl cyclase type 6 (AC6 OE). Results are normalized to the magnitude of the maximal response produced by forskolin (FSK, 10 µM) and IBMX (100 µM) in the same
(C) Size of average FRET responses in control cells (black bars) and AC6 OE cells (red bars). AC6 OE did not significantly affect (P > 0.05, student’s t-test) responses detected by Epac2-MyrPalm (control, n/N = 13/8; AC6 OE, n/N = 8/5), Epac2-CAAX (control, n/N = 20/10; AC6 OE, n/N = 10/7), or Epac2-camps (control, n/N = 13; AC6 OE, n/N = 11/6).

**Figure 3** Changes in cAMP activity associated with lipid raft and non-raft plasma membrane domains following β2AR stimulation in the presence of phosphodiesterase type 4 (PDE4) inhibition. Representative time-course of changes in magnitude of FRET-response (ΔR/R₀) detected by Epac2-MyrPalm and Epac2-CAAX biosensors following inhibition of PDE4 activity with rolipram (10 µM) and subsequent activation of β2ARs with 3 nM isoproterenol (Iso) in (A) untreated human airway smooth muscle (ASM) cells (control) and (B) human ASM cells overexpressing adenylyl cyclase type 6 (AC6 OE). Results are normalized to the magnitude of the maximal response produced by forskolin (FSK, 10 µM) and IBMX (100 µM) in the same cell. (C) Size of average FRET responses in control cells (black bars) and AC6 OE cells (red bars). In the presence of rolipram, there were no significant (P > 0.05, students t-test) differences in the magnitude of the responses to Iso detected by Epac2-MyrPalm in control (n/N = 6/5) and AC6 OE (n/N = 6/4) cells or those detected by Epac2-CAAX in control (n/N = 9/5) and AC6 OE (n/N = 96) cells.
**Figure 4** Changes in cAMP activity associated with lipid raft and non-raft plasma membrane domains following β2AR stimulation in the presence of protein kinase A (PKA) inhibition. Representative time-course of changes in magnitude of FRET-response (ΔR/R₀) detected by Epac2-MyrPalm and Epac2-CAAX biosensors following inhibition of PKA activity with H89 (1 µM) and subsequent activation of β2ARs with 3 nM isoproterenol (Iso) in (A) untreated human airway smooth muscle (ASM) cells (control) and (B) human ASM cells overexpressing adenylyl cyclase type 6 (AC6 OE). Results are normalized to the magnitude of the maximal response produced by forskolin (FSK, 10 µM) and IBMX (100 µM) in the same cell. (C) Size of average FRET responses in control cells (black bars) and AC6 OE cells (red bars). In the presence of H89, there were no significant (P > 0.05, students t-test) differences in the magnitude of the responses to Iso detected by Epac2-MyrPalm in control (n/N = 6/4) and AC6 OE (n/N = 6/4) cells or those detected by Epac2-CAAX in control (n/N = 9/7) and AC6 OE (n/N = 6/4) cells.

**Figure 5** Changes in cAMP activity associated with lipid raft and non-raft plasma membrane domains following β2AR stimulation in cells overexpressing the A kinase anchoring protein (AKAP) disrupting peptide Ht31. (A) Representative time-course of changes in magnitude of FRET-response (ΔR/R₀) detected by Epac2-MyrPalm and Epac2-CAAX biosensors following activation of β2ARs with 3 nM isoproterenol (Iso) in human airway smooth muscle (ASM) cells overexpressing Ht31 and adenylyl cyclase type 6 (AC6 OE). Results are normalized to the magnitude of the maximal response produced by forskolin (FSK, 10 µM) and IBMX (100 µM) in the same cell. (B) Size of
average FRET responses in control cells (black bars) and cells overexpressing AC6 plus Ht31 (red bars). There were no significant (P > 0.05, students t-test with Holm-Sidak correction) differences in the magnitude of the responses to Iso detected by Epac2-MyrPalm in control cells (n/N = 6/6) and cells overexpressing AC6 plus Ht31) (n/N = 10/4) or the magnitude of the responses detected by Epac2-CAAX in control cells (n/N = 7/6) and cells overexpressing Ht31 plus AC6 (n/N = 7/3). Control data from experiments illustrated in figure 1.

**Figure 6** Compartmentalized cAMP signaling in human airway smooth muscle cells. β₂AR stimulation of adenylyl cyclase type 6 (AC6) produces cAMP that is most readily detected by the Epac2-MyrPalm biosensor, which is targeted to lipid raft domains of the plasma membrane, and the Epac2-camps biosensor, which is expressed throughout the cytosolic domain. A kinase anchoring proteins (AKAPs) contribute to the formation of a signaling complex that includes β₂ARs, AC6, type II protein kinase A (PKA), and phosphodiesterase type 4 (PDE4) associated with lipid raft membrane domains. EP₂ prostaglandin receptor (EP₂Rs) stimulation of AC type 2 (AC2) produces cAMP that is most readily detected by the Epac2-CAAX biosensor, which is targeted to non-raft membrane domains.
Figure 1

**Epac2-MyrPalm**

**CONTROL**

A

ΔR/R₀ (% max)

0 10 20 30 40 50 60 70 80 90

Time (min)

Fsk+IBMX

1 nM 3 nM

**Epac2-CAAX**

ΔR/R₀ (% max)

0 10 20 30 40 50 60 70 80 90

Time (min)

Fsk+IBMX

3 nM Iso

1 nM Iso

**Epac2-camps**

ΔR/R₀ (% max)

0 10 20 30 40 50 60 70 80 90

Time (min)

Fsk+IBMX

3 nM Iso

1 nM Iso

**AC6 OE**

B

ΔR/R₀ (% max)

0 10 20 30 40 50 60 70 80 90

Time (min)

Fsk+IBMX

1 nM 3 nM

3 nM Iso

1 nM Iso

**C**

ΔR/R₀ (% max)

0 10 20 30 40 50 60 70 80 90

1 nM isoproterenol

3 nM isoproterenol

* ns
Figure 2

CONTROL

**Epac2-MyrPalm**

![Graph A](https://example.com/graph_a.png)

**Epac2-CAAX**

![Graph B](https://example.com/graph_b.png)

**Epac2-camps**

![Graph C](https://example.com/graph_c.png)

AC6 OE

**Epac2-MyrPalm**

![Graph A](https://example.com/graph_a.png)

**Epac2-CAAX**

![Graph B](https://example.com/graph_b.png)

**Epac2-camps**

![Graph C](https://example.com/graph_c.png)

**A**

<table>
<thead>
<tr>
<th>Time (min)</th>
<th>0</th>
<th>10</th>
<th>20</th>
<th>30</th>
<th>40</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.3</td>
<td>30</td>
<td>60</td>
<td>90</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>30</td>
<td>60</td>
<td>90</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**B**

<table>
<thead>
<tr>
<th>Time (min)</th>
<th>0</th>
<th>10</th>
<th>20</th>
<th>30</th>
<th>40</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.3</td>
<td>30</td>
<td>60</td>
<td>90</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>30</td>
<td>60</td>
<td>90</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**C**

<table>
<thead>
<tr>
<th>Time (min)</th>
<th>0</th>
<th>10</th>
<th>20</th>
<th>30</th>
<th>40</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.3</td>
<td>30</td>
<td>60</td>
<td>90</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>30</td>
<td>60</td>
<td>90</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Graph A**

Epac2-MyrPalm, Epac2-CAAX, and Epac2-camps are shown under CONTROL conditions.

**Graph B**

Epac2-MyrPalm, Epac2-CAAX, and Epac2-camps are shown under AC6 OE conditions.

**Graph C**

A comparison of the responses to butaprost at 0.3 μM and 1 μM in Epac2-MyrPalm, Epac2-CAAX, and Epac2-camps under AC6 OE conditions.

**Legend**

- **ns**: Not significant
Figure 3

**CONTROL**

**Epac2-MyrPalm**

- Time (min): 0 1 2 3 4
- ΔR/R₀ (% max): 0 30 60 90

**Epac2-CAAX**

- Time (min): 0 1 2 3 4 5
- ΔR/R₀ (% max): 0 30 60 90

**AC6 OE**

**A**

- Time (min): 0 10 20 30 40
- ΔR/R₀ (% max): 0 30 60 90

**B**

- Time (min): 0 10 20 30 40 50
- ΔR/R₀ (% max): 0 30 60 90

**C**

- ΔR/R₀ (% max): 0 30 60 90
- rol, rol + Iso
Figure 4

**Epac2-MyrPalm**

**CONTROL**

A

\[\Delta R/R_0 (% \text{ max})\]

0 10 20 30 40

Time (min)

Fsk+IBMX

Iso

H89

**AC6 OE**

B

\[\Delta R/R_0 (% \text{ max})\]

0 10 20 30 40

Time (min)

Fsk+IBMX

Iso

H89

**Epac2-CAAX**

\[\Delta R/R_0 (% \text{ max})\]

0 10 20 30 40

Time (min)

Fsk+IBMX

Iso

H89

C

\[\Delta R/R_0 (% \text{ max})\]

0 20 40 60

H89

H89+Iso
Figure 5

**Epac2-MyrPalm**

**AC6 OE**

<table>
<thead>
<tr>
<th>Time (min)</th>
<th>0</th>
<th>10</th>
<th>20</th>
<th>30</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ΔR/R₀ (%) max</strong></td>
<td>0</td>
<td>30</td>
<td>60</td>
<td>90</td>
</tr>
</tbody>
</table>

**Epac2-CAAX**

<table>
<thead>
<tr>
<th>Time (min)</th>
<th>0</th>
<th>10</th>
<th>20</th>
<th>30</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ΔR/R₀ (%) max</strong></td>
<td>0</td>
<td>30</td>
<td>60</td>
<td>90</td>
</tr>
</tbody>
</table>

**A**

- **Fsk+IBMX**
- **Iso**

**+Ht31**

**B**

- **ns**

<table>
<thead>
<tr>
<th><strong>ΔR/R₀ (%) max</strong></th>
<th>control</th>
<th>AC6+Ht31</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>60</td>
<td></td>
<td></td>
</tr>
<tr>
<td>90</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**AC6 OE**

- **+Ht31**

**Epac2-MyrPalm**

**Epac2-CAAX**
Figure 6